Sodium-Glucose Cotransporter 2 Inhibitor — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the sodium-glucose cotransporter 2 inhibitor class. 208 active patents protecting 2 drugs. First major cliff: 2026. Daily refresh.

2
Drugs in class
208
Active US patents
65/100
Avg vulnerability
$7.1B
Annual revenue covered

Originators

AstraZeneca 144 patents Johnson & Johnson 64 patents

Cliff calendar — next 15 years

4
26
50
27
54
28
35
29
44
30
9
31
2
39
6
40
2
41

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Farxiga
DAPAGLIFLOZIN
 AstraZeneca 144 64 $6.3B 2026-08-18
Invokana
CANAGLIFLOZIN
 Johnson & Johnson 64 65 $800M 2027-07-14

Most attackable patents

Patent Drug Type Vuln Expiry
8329648 Farxiga method of use 80 2026-08-18
8906851 Farxiga method of use 80 2026-08-18
8906851 Farxiga method of use 80 2026-08-18
8329648 Farxiga method of use 80 2026-08-18
8906851 Farxiga other 80 2027-02-18
8906851 Farxiga other 80 2027-02-18
8329648 Farxiga other 80 2027-02-18
8329648 Farxiga other 80 2027-02-18
8501698 Farxiga method of use 80 2027-06-20
8501698 Farxiga method of use 80 2027-06-20

Strongest defences

Patent Drug Type Vuln Expiry
7919598 Farxiga composition of matter 10 2029-12-16
7919598 Farxiga composition of matter 10 2029-12-16
7919598 Farxiga composition of matter 10 2029-12-16
7919598 Farxiga composition of matter 10 2029-12-16
7919598 Farxiga composition of matter 10 2029-12-16
7919598 Farxiga composition of matter 10 2029-12-16
7919598 Farxiga composition of matter 10 2029-12-16
7919598 Farxiga composition of matter 15 2029-12-16
7919598 Farxiga composition of matter 15 2029-12-16
7919598 Farxiga composition of matter 15 2029-12-16

Related